ArticlePloS one2016
Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Safety and immunogenicity of inactivated human Rotavirus vaccine in young children and infants: a randomized, placebo-controlled, double-blind, phase I clinical trial.Nature communications · 2026Trial
- The safety and immunogenicity of inactivated rotavirus vaccine delivered by a dissolving microneedle patch in rats.Human vaccines & immunotherapeutics · 2025Article
- A report for the fifth International Workshop on Rotavirus and Norovirus in China.Human vaccines & immunotherapeutics · 2025Article
- Rotavirus Infections: Pathophysiology, Symptoms, and Vaccination.Pathogens (Basel, Switzerland) · 2025Review
- Gut microbiota modulate immune responses to orally and parenterally administered rotavirus in mice.NPJ vaccines · 2025Article
- Correlates of immune protection against human rotaviruses: natural infection and vaccination.Archives of virology · 2024Review
- Review
- Established and new rotavirus vaccines: a comprehensive review for healthcare professionals.Human vaccines & immunotherapeutics · 2022Review
- Evaluation of efficacy and safety of intradermal delivery of vaccines through microneedle(s) in human beings: a protocol for a systematic review.Systematic reviews · 2022Article
- Rotavirus vaccines: progress and new developments.Expert opinion on biological therapy · 2022Review
- Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine.NPJ vaccines · 2022Article
- Update on rotavirus vaccine underperformance in low- to middle-income countries and next-generation vaccines.Human vaccines & immunotherapeutics · 2021Review
- The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.Expert review of vaccines · 2020Review
- Current and new rotavirus vaccines.Current opinion in infectious diseases · 2019Review
- Rotavirus vaccine protection in low-income and middle-income countries.The Lancet. Infectious diseases · 2019Article
- Ionic Liquids as Potential and Synergistic Permeation Enhancers for Transdermal Drug Delivery.Pharmaceutics · 2019Review
- Rotavirus vaccine efficacy: current status and areas for improvement.Human vaccines & immunotherapeutics · 2019Review
- Noninvasive vaccination against infectious diseases.Human vaccines & immunotherapeutics · 2018Review
- The future control of rotavirus disease: Can live oral vaccines alone solve the rotavirus problem?Vaccine · 2018Article
- Enhancing viral vaccine production using engineered knockout vero cell lines - A second look.Vaccine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Live-attenuated oral rotavirus (RV) vaccines have lower efficacy in low income countries, and additionally are associated with a rare but severe adverse event, intussusception. We have been pursuing the development of an inactivated rotavirus vaccine (IRV) using the human rotavirus strain CDC-9 (G1P[8]) through parenteral immunization and previously demonstrated dose sparing and enhanced immunogenicity of intradermal (ID) unadjuvanted IRV using a coated microneedle patch in comparison with intramuscular (IM) administration in mice. The aim of this study was to evaluate the immune response and protection against RV infection and diarrhea conferred by the administration of the ID unadjuvanted IRV using the microneedle device MicronJet600® in neonatal gnotobiotic (Gn) piglets challenged with virulent Wa G1P[8] human RV. Three doses of 5 μg IRV when administered intradermally and 5 μg IRV formulated with aluminum hydroxide [Al(OH)3] when administered intramuscularly induced comparable rotavirus-specific antibody titers of IgA, IgG, IgG avidity index and neutralizing activity in sera of neonatal piglets. Both IRV vaccination regimens protected against RV antigen shedding in stools, and reduced the cumulative diarrhea scores in the piglets. This study demonstrated that the ID and IM administrations of IRV are immunogenic and protective against RV-induced diarrhea in neonatal piglets. Our findings highlight the potential value of an adjuvant sparing effect of the IRV ID delivery route.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.